On October 11, 2019, the press conference on signing the strategic cooperation agreement between Sichuan International Medical Exchange & Promotion Association (SCIMEA) and Translational Research Center for Medical Innovation (TRI), Sinet Biotechnology Co., Ltd., combined with the launching ceremony of "2019 China-Japan Summit Forum on Advanced Medical and New Drug R&D& Achievements Transformation Conference"was officially held in Shangri-La Hotel Chengdu. Ms. Zhang Mengfan, secretary-general of SCIMEA, Ms. Liu Miaomiao, representative of TRI China andgeneral manager of Sinet Biotechnology Co., Ltd., Mr. Wang Ping, president of Jiemian (Finance New Media) Sichuan, and Mr. Huang Xiao, general manager of BOPP Think Tank attended the meeting.
At the conference, Ms. Zhang Mengfan, secretary-general of SCIMEA, stressed in her speech that the conference, with the theme of "dialogue with top experts, pooling of leading achievements, sharing of investment opportunities and promoting industrial development", with the participation of more than 1,000 people from China and Japan, including officials, scholars, entrepreneurs and scientific research institutes, is a feast of one-on-one dialogues with world-class experts in the field of biomedicine. Moreover, Japan will bring 400 advanced medical technologies and biomedical products that have entered clinical research and development stage under the guidance of academician Tasuku Honjo, the 2018 Nobel Prize winner, to Sichuan for display and transformation.A number of large Japanese pharmaceutical companies will also accompany the visit. China also expects to display and transform more than 500 cutting-edge biomedical achievements.Nearly 100 top domestic investment institutions and more than 200 leading pharmaceutical enterprises will also attend the conference.The conference is bound to become China and Japan's new brand for the transformation of advanced medical achievements and new brand for the settlement of scientific research transformation achievements, laying a solid foundation for starting the new journey of the transformation of China and Japan's advanced medical and new drug research and development achievements in Chengdu.
Ms. Liu Miaomiao, representative of TRI China andgeneral manager of Sinet Biotechnology Co., Ltd. delivered a speech, and noted that she was honored to witness the launch of this grand medical event.In her speech, she pointed out that TRI, as a direct agency of Japan's Food and Drug Administration, is full of confidence and expectation for future cooperation.The conference is undoubtedly the most cutting-edge technology exchange and wisdom exchange in biomedicine through insight into the research and development trend of biomedicine, an interpretation of decision-making basis of venture capital, and a display of the latest scientific research results.Under the leadership of Chairman Tasuku Honjo, a Nobel laureate, TRI will make full use of its advantages in coordinating management and clinical trials, explore in depth the pharmaceutical cooperation opportunities with China, and contribute TRI's wisdom and strength to the development of new drugs and the continuous improvement of the pharmaceutical industry.It is hoped that Chengdu will be turned into an Asian center for biomedical achievement transformation as soon as possible.Sinet relies on TRI to support, invest in, transform and transfer the research and development of new drugs, medical devices and regenerative medicine, which can bring excellent medical research results from China and Japan to medical researchers of the two countries and provide a platform for exchange. He hopes to go further for future cooperation, promote the development of cutting-edge medical technologies in China and Japan, and boost the transformation of advanced medical technologies.
Based on the principles of complementary advantages, mutual benefit and common development, SCIMEA, TRI and Sinet Biotechnology Co., Ltd.concluded a strategic cooperation agreement, with Zhang Mengfan, secretary-general of SCIMEA, and Liu Miaomiao, representative of TRI China andgeneral manager of Sinet Biotechnology Co., Ltd., signing a strategic cooperation agreement under the witness of the media.The three parties all put high hopes for this cooperation, saying that this cooperation is a good opportunity to deepen understanding, enhance friendship and seek common development. It is also a milestone in expanding cooperation areas and accelerating development, and it is of great significance to realize mutual benefit and win-win between China and Japan.All parties will adhere to a sincere and friendly attitude, actively carry out in-depth cooperation in biomedical, scientific research and innovation, commercial investment and other fields, further strengthen the complementing of resources, jointly explore the application and demonstration of advanced medical care, build a benchmark in biomedical industry, incubate new technologies, drugs and standards for future-oriented medicine, and create a new ecology for coordinated development of medicine.
Mr. Wang Ping, president ofSichuan ofjiemian.com (a new media of finance), pointed out that China has become the world's second largest pharmaceutical market, and innovative drug development has entered the acceleration phase. As one of China's influential original financial and economic new media, the pharmaceutical and health industry has always been the focus of jiemian.com Sichuan.He mentioned that the strategic cooperation with SCIMEA will definitely produce a 1+1>2 effect. Jiemian.com will give a full play to the advantages of financial media, publicize the conference in depth, and contribute media strength to promote the transfer and transformation of new drug research and development achievements.
Mr. Huang Xiao, general manager of BOPP Think Tank, mentioned in his speech that the pharmaceutical industry is related to life and health, and is the lasting guarantee of life and health quality.As a knowledge sharing platform for practitioners in the biomedical industry, BOPP Think Tank has been committed to effectively linking various users in the biomedical industry.Taking the opportunity of this summit forum, we will make good use of the advantages of the platform and share the professional resources, knowledge and experience released by the conference. We hope to spare no efforts to promote the balanced development of the pharmaceutical industry and protect people’s health.
< SCIMEA reaches strategic cooperation with BOPP Think Tank>
In the meantime, SCIMEA has also reached strategic cooperation with jiemian.com and Bopp Think Tank.According to report, this conference will adopt all-media publicity and multi-channel communication to further broaden the cooperation, and will form effective traction through on-line and off-line deep integration to promote the depth and height of conference cooperation, accelerate the construction of an all-round Internet medical service system, and realize mutual benefits and win-win!
The signing of these strategic cooperation agreements not only marks the formal start of the "2019 China-Japan Summit Forum on Advanced Medical and New Drug R&D& Achievements Transformation Conference", but also means that all parties have entered a new stage of inclusive development, which can create fertile soil for promoting the exchange of innovative achievements in medical and new drug research and development between China and Japan, set up an international and high-end industry promotion platform, and build an innovative environment for biomedical products in line with international standards.
SCIMEA will take this cooperation as a starting point, give full play to its own advantages, and, through more exchanges and mutual integration, integrate resources of all parties, pool innovation and investment strength of Chinese and Japanese bio-medicine, share new scientific research achievements, discuss new cooperation strategies, and realize powerful combination and leapfrog development, with efforts to make profits for the development of the whole bio-medicine industry chain, benefit the bio-pharmaceutical technological innovation and industrial development, facilitate the upgrading of the pharmaceutical health industry in Sichuan Province and Chengdu, strive to build Chengdu into an Asian center for biomedical achievement transformation, and make the "China-Japan Summit Forum on Advanced Medical and New Drug R&D& Achievements Transformation Conference" widely known.
